You are here: Industry Insights > Market News > Brazil's Anvisa suspends Covaxin shot's emergency use application

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Brazil's Anvisa suspends Covaxin shot's emergency use application

firstwordpharmaJuly 01, 2021

Tag: brazil , Covaxin , COVID-19 , Vaccine

Favorites

Brazil's health regulator has suspended Covaxin's emergency-use application, which was filed by an intermediary on behalf of the COVID-19 vaccine's developer Bharat Biotech, as reported in This is Money.

Brazil's Anvisa suspends Covaxin shot's emergency use application

Anvisa said the intermediary, Precisa, did not submit, or only partially submitted, mandatory and essential documents for the vaccine.

Covaxin has become highly controversial in Brazil over allegations of "irregularities" in the government's efforts to buy 20 million doses.

Previous:Letting children catch Covid may be safer than giving them vaccine, say experts

Next:Tenaya Therapeutics Announces New Appointments to Leadership Team

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem.

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

Brazil's Anvisa suspends Covaxin shot's emergency use application | Pharmasources.com

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

Nucleic Acid Medicines Manufacture, Round 2 call.

Brazil's Anvisa suspends Covaxin shot's emergency use application

Related News

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

You may like